Journal
Multiple Sclerosis and Related Disorders
Publication Date
12-1-2022
Volume
68
First Page
104216
Document Type
Open Access Publication
DOI
10.1016/j.msard.2022.104216
Rights and Permissions
Ontaneda D, Mowry EM, Newsome SD, Naismith RT, Nicholas J, Fisher E, de Moor C, Bohn J, Ho PR, Sandrock A, Rudick R, Williams JR. Benefits of early treatment with natalizumab: a real-world study. Mult Scler Relat Disord. 2022 Dec;68:104216. doi: 10.1016/j.msard.2022.104216. © 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/).
Recommended Citation
Ontaneda, Daniel; Mowry, Ellen M; Newsome, Scott D; Naismith, Robert T; Nicholas, Jacqueline; Fisher, Elizabeth; de Moor, Carl; Bohn, Justin; Ho, Pei-Ran; Sandrock, Al; Rudick, Richard; and Williams, James R, "Benefits of early treatment with natalizumab: A real-world study." Multiple Sclerosis and Related Disorders. 68, 104216 (2022).
https://digitalcommons.wustl.edu/oa_4/1341
Department
ICTS (Institute of Clinical and Translational Sciences)
